Publications by authors named "Frederick Libeer"
Article Synopsis
- - An amendment to the original paper has been released.
- - The amendment provides updates or corrections to the initial findings.
- - Readers can access the amendment through the original article link.
Article Synopsis
- An amendment to the original paper has been released.
- This amendment provides updates or corrections to the original content.
- You can find and access the amendment through the original article link.
Article Synopsis
- - The study investigates whether GM-CSF, a protein that boosts antiviral immunity, can help improve lung function in COVID-19 patients with acute lung injury by enhancing oxygenation by 25%.
- - It's designed as a phase 4, randomized controlled trial involving patients aged 18-80 who recently experienced severe COVID-19 symptoms and respiratory failure, with specific exclusion criteria for certain health conditions and treatments.
- - Participants will receive inhaled sargramostim alongside regular care for 5 days, with a switch to intravenous treatment if their condition worsens, and possibly extended treatment based on their progress.
Article Synopsis
- The study aims to evaluate the safety and effectiveness of blocking specific immune pathways (IL-6 and IL-1) against standard care in COVID-19 patients experiencing acute respiratory failure and systemic cytokine release syndrome.
- It is a phase 3, multi-center, open-label trial with participants being adult patients diagnosed with recent COVID-19 infections and acute hypoxia, recruited from 16 hospitals in Belgium.
- Participants will be randomly assigned to one of five treatment groups involving different combinations of immune blockers (Anakinra, Siltuximab, and Tocilizumab) or receive standard medical care.
